Table 1 Clinical characteristics and secondary KRAS mutation status of Group A, Group B, and Group C.
Clinical characteristics | Group A (n = 13) | Group B (n = 16) | Group C (n = 21) |
|---|---|---|---|
Gender (male/female) | 9/4 | 11/5 | 15/6 |
Age, years (median, range) | 52 (30–72) | 51.5 (30–73) | 51 (27–75) |
Site of primary tumor (right colon/left colon/rectum) | 4/3/6 | 5/8/3 | 4/7/10 |
The method of acquiring tumor samples for first KRAS detection (surgery/colonoscopy) | 13/0 | 4/12 | 15/6 |
Therapy regimens (chemo alone/chemo + cetuximab) | 12/1 | 7/9 | 5/16 |
Nature of chemotherapy (adjuvant/first-line) | 13/0 | 0/16 | 0/21 |
Number of therapy courses (median, range) | 8.7 (4–12) | 5.4 (3–12) | 17.5 (2–55) |
Duration of therapy, months (median, range) | 5.5 (2.3–10.6) | 3.8 (1.6–6.8) | 14.9 (1.4–50.1) |
Time from relapse/progression to 2nd KRAS detection, days (median, range) | 58.4 (5–336) | 0 | 21 (1–230) |
Site of second tumor sampling (colorectum/liver/others) | 7/2/4 | 16/0/0 | 3/10/8 |
Sampling method for second KRAS detection (surgery/biopsy/colonoscopy) | 12/1/0 | 16/0/0 | 6/13/2 |
Outcome of second KRAS detection (wild-type/mutation) | 13/0 | 16/0 | 18/3 |
Secondary KRAS mutation rate (%) | 0 | 0 | 14.3 |
